FDA.reportPublic FDA data

voxelotor 300 MG Tablet for Oral Suspension

RxCUI
2588070
RxNorm name
voxelotor 300 MG Tablet for Oral Suspension
Display name
voxelotor 300 MG Tablet for Oral Suspension
Full name
voxelotor 300 MG Tablet for Oral Suspension
Term type
PSN
Status
DailyMed mapping
Updated
2026-06-04 23:38:54

RxNav Current And Historical NDCs#

RxNav current and historical NDC rows page 1 of 1 · 0 matching rows.

No records found.

UNII Substances#

UNII substance links page 1 of 1 · 0 matching rows.

No records found.

openFDA label cross-check#

OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.

Matched openFDA labels page 1 of 1 · 1 matching rows.

Brand, Generic, Manufacturer table
BrandGenericManufacturerSPL set IDEffective dateAvailable safety fieldsJoin
OXBRYTAVOXELOTORGlobal Blood Therapeutics, Inc, A subsidiary of Pfizer Inc.3c557fac-29ec-483f-b691-8a935d4decc32023-12-26Warnings, Adverse reactionsExact identifier
rxcui: 2588070

Reported adverse events (FAERS/openFDA)#

Adverse event summaries are temporarily unavailable. Other product information remains available.

DailyMed RxNorm Mappings#

unique DailyMed labels mapped to this RxNorm concept page 1 of 1 · 1 matching rows.

Set ID, RxNorm mappings, Terms table
Set IDRxNorm mappingsTermsSPL versionLabelEffective
3c557fac-29ec-483f-b691-8a935d4decc3voxelotor 300 MG Tablet for Oral Suspension [PSN] · voxelotor 300 MG Tablet for Oral Suspension [SCD]213These highlights do not include all the information needed to use OXBRYTA safely and effectively. See full prescribing information for OXBRYTA. OXBRYTA ® (voxelotor) tablets, for oral use OXBRYTA ® (voxelotor) tablets for oral suspension Initial U.S. Approval: 201920231226